Merck KGaA
https://www.merckgroup.com/en
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Merck KGaA
First-Line Bavencio Bladder Cancer OK Boosts Merck KGaA
Pfizer-partnered Bavencio has struggled to compete with other checkpoint inhibitors like Keytruda, Opdivo, Imfinzi and Tecentriq, but could carve out a lucrative niche in first-line urothelial carcinoma.
Boston Scientific Bets Big On Monitoring; Buys Preventice For Up To $1.25Bn
The deal is the fourth major acquisition in the remote monitoring market in the last five weeks after Philips acquired BioTelemetry and Capsule and Hillrom bought Bardy Diagnostics.
GSK Ends Tough Week With Ulcerative Colitis Therapy Termination
If bad luck comes in threes, GSK will be delighted to see the end of this week with dostarlimab approval delayed, bintrafusp failing in lung cancer and a Phase II of an ulcerative colitis drug discontinued.
Lung Cancer Failure Isn't The End For Merck KGaA And GSK's Bintrafusp
Key cancer asset is still looking for a Phase III validation after failing to outperform Keytruda in challenging frontline NSCLC setting.
Company Information
- Industry
- Pharmaceuticals
- Research, Analytical Equipment & Supplies
-
Pharmaceuticals
- Drug Delivery
- Nutraceuticals
-
Biotechnology
- Synthesis Technologies, Production Processes
-
Drug Discovery Tools
-
Molecular Diversity
- Natural Products
-
Molecular Diversity
- Other Names / Subsidiaries
-
- Acadiana Ventures Inc.
- Allergopharma Joachim Ganzer KG
- AmpTec GmbH
- Asceneuron
- EMD Pharmaceuticals
- Grzybowski Scientific Inventions (GSI)
- Intermolecular Inc
- JRH Biosciences
- Merck Hoei Ltd.
- Millipore
- MilliporeSigma
- Ormet Circuts Inc.
- Serono
- EMD Serono, Inc.
- Sigma-Aldrich
- Versum Materials, Inc.